NASDAQ · NSPR
Healthcare · Medical - Devices
$0.66
Up+$0.12 (+18.71%)
Updated Nov 5, 2026, 1:06 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NSPR
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
NSPR closed at $0.66 after 20 trading sessions, up 28.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $0.506 | $0.6757 | $0.506 | $0.6579 | 561.01K |
| Nov 2, 2026 | $0.47 | $0.5724 | $0.459 | $0.539 | 650.77K |
| Oct 30, 2026 | $0.44 | $0.4729 | $0.44 | $0.45 | 478.66K |
| Oct 29, 2026 | $0.46 | $0.48 | $0.4418 | $0.4514 | 207.12K |
| Oct 28, 2026 | $0.4477 | $0.48 | $0.44 | $0.468 | 524.8K |
| Oct 27, 2026 | $0.448 | $0.475 | $0.431 | $0.455 | 390.78K |
| Oct 26, 2026 | $0.459 | $0.50 | $0.4349 | $0.45 | 301.38K |
| Oct 23, 2026 | $0.47 | $0.4999 | $0.44 | $0.4493 | 172.13K |
| Oct 22, 2026 | $0.461 | $0.4899 | $0.4393 | $0.455 | 512.46K |
| Oct 21, 2026 | $0.43 | $0.4675 | $0.4254 | $0.4481 | 850.66K |
| Oct 20, 2026 | $0.4537 | $0.4785 | $0.434 | $0.4385 | 70.64K |
| Oct 19, 2026 | $0.451 | $0.526 | $0.4366 | $0.44 | 122.65K |
| Oct 16, 2026 | $0.4783 | $0.4849 | $0.45 | $0.4552 | 94.63K |
| Oct 15, 2026 | $0.485 | $0.5117 | $0.4801 | $0.4804 | 60.98K |
| Oct 14, 2026 | $0.484 | $0.50 | $0.4604 | $0.4682 | 198.66K |
| Oct 13, 2026 | $0.5423 | $0.5738 | $0.4807 | $0.50 | 96.63K |
| Oct 12, 2026 | $0.5196 | $0.5399 | $0.4897 | $0.4916 | 90.66K |
| Oct 9, 2026 | $0.5136 | $0.59 | $0.4897 | $0.521 | 327.22K |
| Oct 8, 2026 | $0.50 | $0.53 | $0.4604 | $0.48 | 225.42K |
| Oct 7, 2026 | $0.535 | $0.5949 | $0.496 | $0.514 | 145.45K |
The latest Smart Investors Daily articles mentioning NSPR.
Company
Market Activity
Research & News
NSPR research
Company profile and research snapshot.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 5, 2026 | Piper Sandler | Overweight | — |
| May 12, 2025 | Piper Sandler | Overweight | — |
| Dec 11, 2024 | Lake Street | Buy | — |
| Sep 17, 2024 | Piper Sandler | Overweight | — |
| Nov 2, 2023 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Benzinga · Oct 16, 2026
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares increased by 27.9% to $2.79 during Friday's pre-market session. The company's market cap stands at $5.2 million. Picard Medical (AMEX:PMI) stock moved upwards
Yahoo · Sep 21, 2026
- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 - - The amended warrants, if exercised in full, together with existing cash balances, expected to provide additional resources to fund launch of CGuard Prime 80 cm following FDA approval - - No additional warrants issued in connection with the amendments - MIAMI, Sept. 21, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireM
Benzinga · Sep 17, 2026
InspireMD (NASDAQ:NSPR) reported second-quarter financial results on Monday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by Benzinga
Yahoo · Sep 4, 2026
MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 23,764 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of September
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NSPR.
